Summit Partners Public Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Summit Partners Public Asset Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$62.4M	Sell	787,263 -616,770	-44%	-$46.4M	1.1%	23
2026 Q1	$105M	Sell	1,404,033 -58,673	-4%	-$4.63M	2.83%	6
2025 Q4	$116M	Buy	1,462,706 +712,706	+95%	+$53.7M	2.41%	8
2025 Q3	$49.1M	Buy	+750,000	New	+$36.6M	1.02%	31

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Summit Partners Public Asset Management's IONS Position: Q2 2026 in Review

Summit Partners Public Asset Management reduced its Ionis Pharmaceuticals (IONS) stake by 44% in Q2 2026, selling an estimated $46.4M and leaving 787,263 shares worth $62.4M. The position accounts for 1.1% of the portfolio, ranked #23.

Summit Partners Public Asset Management first reported a position in IONS in Q3 2025 and has held it in 4 quarters since. The position peaked at $116M in Q4 2025. 513 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Summit Partners Public Asset Management held 787,263 shares of Ionis Pharmaceuticals worth $62.4M as of Q2 2026.
Summit Partners Public Asset Management sold 616,770 Ionis Pharmaceuticals shares in Q2 2026, an estimated $46.4M.
Ionis Pharmaceuticals made up 1.1% of Summit Partners Public Asset Management's portfolio in Q2 2026, its #23 holding.
Summit Partners Public Asset Management first reported a position in Ionis Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
Summit Partners Public Asset Management's Ionis Pharmaceuticals position peaked at $116M in Q4 2025.
513 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Summit Partners Public Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.